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OBJECTIVES We undertook the review of all available cases of hypersensitivity reactions after placement of
a drug-eluting stent (DES) and classified potential causes.
BACKGROUND Six months after the approval of the first DES, the Food and Drug Administration (FDA)
reported 50 hypersensitivity reactions after stent placement but later concluded these were due
to concomitantly prescribed medications such as clopidogrel. Nevertheless, the FDA
continued to receive reports of hypersensitivity.
METHODS Reports available from April 2003 through December 2004 for hypersensitivity-like reactions
associated with the sirolimus-eluting stent (CYPHER, Cordis Corp., Miami Lakes, Florida) and
paclitaxel-eluting stent (TAXUS, Boston Scientific Corp., Natick, Massachusetts) were reviewed.
Sources of reports included the FDA’s adverse-device-event database, the published literature, and
investigators from the Research on Adverse Drug/Device events And Reports (RADAR) project.
Causality was assessed using standardized World Health Organization criteria.
RESULTS Of 5,783 reports identified for the DES in the FDA database, 262 unique events included
hypersensitivity symptoms. Of these reports, 2 were certainly and 39 unlikely caused by
clopidogrel and 1 was certainly, 9 probably, and 13 unlikely caused by the DES. From all
sources, we identified 17 distinct cases that were probably or certainly caused by the stent, of
which 9 had symptoms that lasted longer than four weeks. Four autopsies confirmed
intrastent eosinophilic inflammation, thrombosis, and lack of intimal healing.
CONCLUSIONS The FDA reports and autopsy findings suggest that DES may be a cause of systemic and
intrastent hypersensitivity reactions that, in some cases, have been associated with late
thrombosis and death. (J Am Coll Cardiol 2006;47:175–81) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.071College of Cardiology Foundation
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(ince being approved by the Food and Drug Administration
FDA), drug-eluting stents (DES) have reduced the occur-
ence of major cardiac events from 16.4% with bare-metal
tents to 7.8% with DES (1). The stainless steel struts of the
tent are coated with polymers impregnated with a drug that
From the *Veterans Administration Salt Lake City, Salt Lake City, Utah;
Veterans Administration Chicago, Chicago, Illinois; ‡Veterans Administration San
ntonio, San Antonio, Texas; §Veterans Administration Albuquerque, Albuquerque,
ew Mexico; University of Utah, Salt Lake City, Utah; ¶Northwestern University,
hicago, Illinois; #University of Texas Health Science Center at San Antonio, San
ntonio, Texas; **University of New Mexico, Albuquerque, New Mexico; ††Armed
orces Institute of Pathology, Bethesda, Maryland; and ‡‡Yale University, New
aven, Connecticut. Grant support from Veterans Administration Health Services
esearch & Development RCD-02-176, TRP-02-147, the Geriatric Research,
ducation, and Clinical Center (GRECC) of the VA Salt Lake City Health Care
ystem, and from the National Cancer Institute (1R01CA, 102713-01, and P 30
A60553). Dr. Virmani has received research support from Boston Scientific in the
ast three years. Dr. Feldman is a co-founder of Setagon Inc., a developer of a
rug-eluting metallic stent. This work has been presented as an abstract at the
ollowing scientific meetings: 2004 American Heart Association Scientific Sessions,
nd 2005 American College of Cardiology Scientific Sessions.c
Manuscript received May 2, 2005; revised manuscript received June 6, 2005,
ccepted July 6, 2005.nhibits local intimal hyperplasia. The sirolimus-eluting
tent (SES) (CYPHER, Cordis Corp., Miami Lakes, Flor-
da), approved by the FDA in May 2003, is impregnated
See page 182
ith an anti-inflammatory agent. The paclitaxel-eluting
tent (PES) (TAXUS, Boston Scientific Corp., Natick,
assachusetts), approved in March 2004, is impregnated
ith a chemotherapeutic agent. More than two million
ES have been implanted, now accounting for 75% of all
oronary artery stents utilized (2,3).
In October 2003, an FDA advisory described 50 hyper-
ensitivity cases after CYPHER stent implantation (4).
ymptoms included rash, dyspnea, hives, itching, and fe-
ers. In November 2003, a follow-up advisory indicated that
lmost all of the hypersensitivity reactions were caused by
tandard drug therapy associated with stent implantation
5). Nevertheless, components of DES and closely related
ompounds have caused hypersensitivity reactions in other
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Hypersensitivity Reactions to Drug-Eluting Stents January 3, 2006:175–81ettings, suggesting that components of the stent itself may
e causative factors in some cases (6–8). Moreover, there
as been no public verification of the FDA case-based
ndings through epidemiologic analysis of clinical trial data;
ypersensitivity data is not presented in the package insert
r in publications of the clinical trials (9,10).
The recently initiated Research on Adverse Drug/Device
vents And Reports (RADAR) project reviews in detail
dverse event reports gathered from diverse sources, includ-
ng the FDA, in order to evaluate causal associations
etween therapeutic agents and potentially fatal adverse
vents (11). Herein, RADAR investigators assessed all
vailable cases to date for the possibility that DES may be a
ause of hypersensitivity reactions, including cases identified
ndependent from the FDA database.
ETHODS
he FDA’s Manufacturer and User Device Experience
enter (MAUDE) receives adverse event reports from de-
ice monitoring programs worldwide (12). All MAUDE
eports regarding the CYPHER and TAXUS stents re-
eived from April 2003 through December 2004 were
eviewed. The case definition included DES placement and
ypersensitivity findings including rash, dyspnea, hives,
naphylaxis, thrombocytopenia, itching, arthralgia, joint
welling, myalgia, or fevers. Reports were reviewed for
imilar dates, location, and clinical findings to minimize
ouble counting of events. Other instances of DES-
ssociated hypersensitivity reactions were identified by
eview of electronic databases (medical subject headings
erms of DES, hypersensitivity) and/or from the clinical
ractice of study co-investigators.
Fields in the MAUDE database used for analysis and
lassification included the event identification, report identifi-
ation, date received, seriousness of outcome according to
DA criteria (death, life-threatening, hospitalization, emer-
ency intervention), source of report (manufacturer or other),
nd free text descriptions. Reviewers were blinded to all data
xcept the event identification, report identification, and free
ext descriptions of the case. Reviewers coded the time from
mplantation to onset of symptoms (“immediately afterwards”
lassified as one day, and “soon after” classified as five days),
uration of symptoms (no time stated but one physician visit
ith subsequent telephone follow-up classified as four weeks),
Abbreviations and Acronyms
DES  drug-eluting stent
FDA  Food and Drug Administration
MAUDE Manufacturer and User Device Experience
PES  paclitaxel-eluting stent
RADAR  Research on Adverse Drug/Device events
And Reports
SES  sirolimus-eluting stent
WHO  World Health Organizationash type, rash distribution, other symptoms, allergy history,
*
reported attribution of cause to stent, reported attribution of
ause to concomitant medication, treatments (for each: drug/
ntervention, duration, effect), concomitant medication (for
ach: physician attribution of cause for symptoms, started more
han seven days before stent, previous continuous exposure
ithout reaction).
Causal association grades for clopidogrel, aspirin, and the
ES were assigned according to World Health Organiza-
ion (WHO) criteria (13). These criteria classify causal
ssociations as certain, probable, possible, or unlikely based
n timing, pathophysiology, de-challenge (agent with-
rawal), re-challenge (agent re-exposure), and competing
xplanations (Table 1).
The crude odds ratio was used as the measure of association
etween the source of the report and the presence of a causal
ttribution statement. The kappa statistic was used to measure
greement between the reported cause of the reaction and the
HO-criteria-based classification dichotomized between proba-
le and possible scores. All statistical analyses were conducted
sing Stata 8.2 (StataCorp., College Station, Texas).
ESULTS
ince DES have been marketed, we identified 5,781
AUDE reports received by the FDA (3,695 for
YPHER over 18 months and 2,086 for TAXUS over 8
onths). Of these, 251 reports for CYPHER and 11
eports for TAXUS described hypersensitivity symptoms.
igure 1 demonstrates an increase from a monthly mean of
0 to 44 after the release of the FDA caution. The four
able 1. Application of World Health Organization Criteria to
otential Causal Agents
Agent Classification Criteria*
nti-platelet agents Certain if the hypersensitivity findings resolved
on dechallenge and recurred on re-challenge.
Probable if the reaction resolved after
dechallenge.
Unlikely if there was prior, continuous
exposure without hypersensitivity findings or
no change in hypersensitivity findings in
response to dechallenge or re-challenge.
ntravenous agents
used at
Certain if the hypersensitivity findings resolved
on dechallenge and recurred on re-challenge.
implantation Probable if the reaction began the day of
implantation and resolved within two days.
Unlikely if the reaction began more than 2
days after use of these agents.
rug-eluting stents Certain if there was histological evidence of
eosinophilic reaction confined to the area of
the stent at autopsy.
Probable if all other potential causes were
scored as unlikely (all medications we
discontinued) and there was evidence of a
persistent allergic response for at least two
weeks’ duration.
Unlikely if another agent was identified as a
probable or certain cause.If no cause was otherwise classifiable, it was classified as possible. Some cases required
eferral to the original World Health Organization criteria for final classification.
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January 3, 2006:175–81 Hypersensitivity Reactions to Drug-Eluting Stentsonths after the FDA retraction of the hypersensitivity
aution, a mean of 25 reports were received. The number of
eports received by the FDA decreased to zero thereafter.
Among MAUDE hypersensitivity reports with symptom
nset information (n  185), symptoms began within 1 day
f stent implantation (20%), 2 to 7 days (46%), 8 to 14 days
19%), and 2 weeks (15%) after stent implantation (mean
1.5 days). Among the 115 cases for which symptom
uration information was available, symptoms persisted for
1 week for 15% of cases and30 days for 50%. Presenting
ymptoms included rash (78%), itching (27%), hives (23%),
yspnea (16%), fever (13%), atypical chest pain (8%), high
r low blood pressure (8%), joint pain or swelling (8%), and
naphylaxis (6%). Among hypersensitivity reports with de-
criptions of rash (n  204), 26% involved hives, 3%
nvolved desquamation or blisters, 21% covered the entire
ody, 11% were focal eruptions, and 57% lacked character-
zing information. Based on MAUDE seriousness codes (n
242) and additional classifications from case descriptions
n  8), 95% of hypersensitivity reactions were classified as
erious including events that required emergency interven-
ions (34%) (e.g., intravenous steroids and cardiac catheter-
zation) or hospitalization (18%), or resulted in permanent
isability (5%), or may have contributed to death (2%). At
Figure 1. Reports received by the Food and Drug Administration for h
Table 2. World Health Organization Causatio
Hypersensitivity Identified in the MAUDE Da
Putative Causative Agent Certain
Clopidogrel 2 (1%)
Aspirin 0
Agents administered during
implantation
0
CYPHER stent 1 (1%)
TAXUS stent 0For percent values, each agent is denominated by the number of ceast one antiplatelet drug was discontinued at the onset of
ypersensitivity in 19% of cases.
Potential causative factors—concomitant medications
ersus the DES—were evaluated using WHO criteria (Ta-
les 1 and 2). Lack of key information resulted in simulta-
eous classifications of “possible” for the three major causes
f hypersensitivity (clopidogrel, aspirin, and the DES) in
0% of reports. Over one-fifth of all MAUDE hypersensi-
ivity reactions, of which three were fatal, persisted more
han 30 days but could not be scored above “possible” for
ny cause because of lacking information.
From the MAUDE database, cases seen by RADAR
o-investigators (14), and published cases (15), 17 cases (14
YPHER and 3 TAXUS) of probable or certain DES-
nduced hypersensitivity syndromes were identified (Table
). Four patients died of coronary thrombosis that extended
nto the stent. Histological examination demonstrated in-
rastent eosinophilic infiltrates and poor intimal healing as
ate as 18 months after implantation (Fig. 2). In one of these
atients, concomitantly placed bare-metal stents were not
ssociated with these hypersensitivity findings. For all 17
ases, clinical manifestations included non-urticarial rash (n
8), hives (n  5), dyspnea (n  6), myalgia/arthralgia (n
3), itching (n  2), and blisters (n  1). All urticarial
ensitivity-like symptoms associated with drug-eluting coronary stents.
sessment Categories for Associated
se
robable Possible Unlikely
0 221 (84%) 39 (15%)
0 240 (92%) 22 (8%)
3 (1%) 13 (5%) 246 (93%)
7 (3%) 230 (92%) 13 (5%)
2 (18%) 9 (82%) 0n As
taba
Pases in which the agent was used.
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Hypersensitivity Reactions to Drug-Eluting Stents January 3, 2006:175–81ruptions began within 10 days of implantation. Laboratory
ndings included eosinophilia and elevated IgE titers over
ve times normal for three patients. Clinical or laboratory
ndings did not abate with discontinuation of antiplatelet
edications.
We also evaluated the MAUDE dataset for completeness
nd potential bias. Many MAUDE reports did not include
nformation on time to symptom onset (30%), time of
ymptom duration (55%), concomitant drugs (40%), and
e-challenge response to concomitant drugs (81%). In
omparison to reports submitted from sources other than
he manufacturer, manufacturer reports were 3.4-fold (95%
able 3. Findings for 17 Individuals With Hypersensitivity Symp
rug-Eluting Stent
Patient
Number Data Source Stent
Days From
Implantation to
First Symptom
Dura
Symptom
ases with focal hypersensitivity on autopsy scored as certainly caused by
1 RADAR T 150
2 RADAR C 30
3 MAUDE* C 78 N
4 RADAR (14) C 21
ases with generalized hypersensitivity scored as probably caused by the s
5 MAUDE C 3
6 MAUDE C 4
7 MAUDE C 1
8 MAUDE C 2
9 MAUDE C 0.25
0 MAUDE C 4
1 MAUDE C NA
2 MAUDE T 10
3 MAUDE T 9
4 RADAR C 21 
5 RADAR C 4
6 RADAR C 14
7 Case report (15) C 210 
uration indicated by “” was approximate time through the end of follow up.
iscontinued. *Case 3 and 4 had similar timing and findings but different coronary a
A  attenuated (symptoms persisted at low level or returned after prednisone ho
vailable; R  resolved (symptoms completely resolved after course of prednisone); Tonfidence interval 1.0 to 17.7) more likely to include a htatement that the DES was not the cause of the hypersen-
itivity symptoms and 3.1-fold (95% confidence interval 1.1
o 12.6) more likely to include text indicating that clopi-
ogrel was the most likely cause of the hypersensitivity
ymptoms. Agreement was low between the likelihood that
lopidogrel was the most probable cause of the hypersensi-
ivity findings included in the MAUDE database versus our
eview (kappa  0.05).
ISCUSSION
his study is the first comprehensive assessment of
Classified as Certainly or Probably Due to a
of
eeks) Hospitalization
Non-Urticarial
Rash Urticaria Dyspnea
tent
   
   
   
   
   
   
  
   
   
   
   
   
   
   
   
   
   
eral eosinophilia and IgE elevation was determined after anti-platelet drugs were
y and were reported from different regions.
BMS  bare-metal stent; C  CYPHER; DES  drug-eluting stent; NA  not
AXUS.toms
tion
s (w
the s
0
12
A
3
tent
4
2
4
8
4
4
4
2
1
40
40
4
16
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January 3, 2006:175–81 Hypersensitivity Reactions to Drug-Eluting Stentsf DES. Only 2 of 262 cases of hypersensitivity cases
eported to the FDA could be attributed to clopidogrel
espite the widespread perception that this antiplatelet
gent is the major culprit for hypersensitivity reactions. For
7 cases, the stent itself appears to be the most probable
ause of hypersensitivity findings. Pathology findings from
our autopsies present the strongest evidence that DES
ause hypersensitivity reactions.
Medications initiated after DES implantation are a pos-
ible source of hypersensitivity-like symptoms. About 4% of
ersons who receive intravenous iodinated contrast agents
evelop rashes or itching, with symptoms usually beginning
ithin minutes of contrast administration (16). For ticlopi-
ine, clopidogrel, and aspirin, rash is reported in 5.1%,
.2%, and 3.5% of recipients, respectively (16). In a pro-
able 3. Continued
Elevated IgE or
Eosinophilia Other Symptoms Other Fin
NA In-stent thrombosis and death
at 5 months
Eosinophilic infilt
DES but not w
BMS, of which
placed 2 month
and one simult
NA In-stent thrombosis and death
at 4 months
Eosinophilic infilt
of stent on auto
NA In-stent thrombosis and death
at 18 months
Eosinophilic infilt
of stent on auto
NA In-stent thrombosis and death
at 18 months
Eosinophilic infilt
of stent on auto
NA Painful, swollen joints, fever,
itching
Bare-metal stent
year
 Anaphylaxis NA
NA Headache, intermittent
hypertension
NA
NA Itching NA
NA Hypertension NA
NA Urticaria worsened after
second CYPHER™ stent
NA
NA NA NA
NA Dysphagia, joint pain, aches History of allergy
catheters
NA Dysphagia NA
 Itching, blisters on hands Previously tolerate
intermittent asp
 Hypertension Skin biopsy consi
drug reaction w
drugs, gallium-
in carinal node
 Weakness, cough, fever Broncoscopy prov
eosinophilic pn
Rechallenge to
without hypers
response.
NA Myalgia Gallium-67 uptak
stentpective study of 130 patients who received ticlopidine and hspirin after a bare-metal stent, the mean onset of hyper-
ensitivity symptoms was 10 days, and mean duration was 5
ays; no case lasted longer than 30 days (17). Although
DA officials concluded that most of the CYPHER stent-
ssociated hypersensitivity reactions could be attributed to
oncomitant drugs, particularly antiplatelets, our analysis
uggests that, in all but two cases, clopidogrel would be
lassified as a possible or an unlikely cause of the clinical
ndings. Moreover, the duration of symptoms in the
AUDE dataset, in which 50% of cases lasted more than a
onth, is not congruent with the shorter duration of
ymptoms in patients receiving ticlopidine after bare-metal
tents (17). It is particularly important not to misattribute
he cause of hypersensitivity to antiplatelet medications, as
remature discontinuation of these drugs increases the
Medications
Started at
Implantation
Discontinued
Medications
Response to
Prednisone
within
3
were
ier
sly
None None —
at site
Fig. 2)
Aspirin, clopidogrel None —
at site NA NA
at site Ticlopidine, aspirin,
simvastatin, beta-
blocker
Ticlopidine —
evious None None A
Aspirin, clopidogrel Aspirin, clopidogrel R
NA Aspirin, clopidogrel —
Clopidogrel Clopidogrel A
None None A
NA Clopidogrel —
Clopidogrel Clopidogrel A
scular NA Clopidogrel A
None None A
Aspirin, clopidogrel Clopidogrel —
with
ff all
take
Clopidogrel Aspirin, clopidogrel A
nitis.
ogrel
ity
Clopidogrel Clopidogrel R
ite of NA NA —dings
rates
ithin
two
s earl
aneou
rates
psy (
rates
psy
rates
psy
the pr
to va
d
irin
stent
hile o
67 up
en
eumo
clopid
ensitiv
e at sazard of stent thrombosis 90-fold (18).
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Hypersensitivity Reactions to Drug-Eluting Stents January 3, 2006:175–81Drugs impregnated in the stent may also be a source of
ypersensitivity. Sirolimus is an unlikely cause of hypersen-
itivity because it typically reduces eosinophilic infiltration
nd histamine release and has been associated with low rates
f hypersensitivity (16). The incidence of hypersensitivity to
aclitaxel itself is not known because large, published
tudies have used a castor-oil-derived vehicle known to have
igh rates of non-immune-mediated hypersensitivity reac-
ions (19).
Non-drug components of the DES are potential causes of
ypersensitivity. The polymer coating can fragment and
xpose metal struts (14), raising concern that nickel and
olybdenum in the stainless steel may cause hypersensitiv-
ty (6). However, bare-metal stents have not been demon-
trated to cause hypereosinophilic, IgE-mediated reactions
n a human autopsy series of over 400 stents (14). The
olymers coating the DES are a more likely cause of late,
ersistent hypersensitivity. Studies of related polymers have
emonstrated local and systemic hypersensitivity responses
o intravascular and locally applied polymers (7). In animal
tudies of DES, eosinophilic infiltrates developed in 25% of
igs receiving DES, and these infiltrates were more prom-
igure 2. Photomicrograph of the non-stented coronary artery of Patient #
hrombus (th) (A). In B is shown the proximal stented artery with marked in
reas in B is shown in C and D, note that there is severe granulomatous
etween the stent struts, there is severe eosinophilic and T-cell infiltration (h
s absence of endothelium in D; instead there is a surface thrombus.nent at 90 days versus 28 days (14). eThe limitations of our study should be acknowledged.
irst, hypersensitivity events in DES clinical trials are likely
o be underreported, as some trials (9,10) solicited events
hat were judged by the treating clinician to be attributable
o the stent instead of all hypersensitivity events. Moreover,
he proportion of 262 cases in over two million insertions is
ell below the 4% expected for hypersensitivity from drugs
lone. Second, MAUDE reports frequently lacked informa-
ion necessary for causality attribution. Third, because of
nderreporting and missing case information, it is not
ppropriate to draw inferences that hypersensitivity reac-
ions are more frequently caused by the stent than concom-
tant drugs or by one brand of stent than another. As with
ost of the reports from the RADAR project (11), inci-
ence rate estimates are not possible to derive from spon-
aneous reports. However, because clinical trials with thou-
ands of patients have not reported increased mortality with
ES compared to bare-metal stents (9,10), the incidence of
atal hypersensitivity events due to DES is likely to be low.
In conclusion, our findings suggest that local and sys-
emic hypersensitivity manifestations can develop in re-
ponse to implantation of DES in coronary arteries. These
t proximal to the stent showing severe stenosis and non-occlusive luminal
atory reaction around stent struts; high-power magnification of the boxed
ion consisting of macrophages (arrowheads) and giant cells (arrows). In
ower E) with only rare spindle-shaped cells seen close to the lumen. There2 jus
flamm
reactvents may cause prolonged hypersensitivity symptoms and
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January 3, 2006:175–81 Hypersensitivity Reactions to Drug-Eluting Stentsccasionally result in death. Further study is warranted to
haracterize the incidence and course of these events, to
evelop tests that predict or confirm the development of
tent-associated hypersensitivity, and to determine whether
tent-sensitive patients warrant prolonged antiplatelet ther-
py. Health professionals should be vigilant for hypersensi-
ivity symptoms among persons receiving a DES and should
ubmit detailed adverse event reports to the manufacturer or
he FDA.
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